Bacteria develop resistance to lincomycins primarily through alterations in their ribosomal target sites. Specifically, mutations in the 23S rRNA gene, a component of the bacterial ribosome, hinder lincomycin binding. This prevents the antibiotic from inhibiting protein synthesis, allowing the bacteria to survive and multiply.
Another significant mechanism involves enzymatic inactivation. Bacteria produce enzymes, such as lincosamide nucleotidyltransferases (LNTs), that modify the lincomycin molecule. This modification renders the antibiotic ineffective.
Efflux pumps are membrane proteins that actively transport antibiotics out of the bacterial cell. Increased expression or enhanced function of these pumps effectively lowers the intracellular concentration of lincomycin, reducing its impact. Understanding the specific pumps involved–such as those belonging to the major facilitator superfamily (MFS)–is crucial for developing countermeasures.
Finally, changes in bacterial cell permeability can also contribute to resistance. Altered porin proteins, which control the passage of molecules across the outer membrane in Gram-negative bacteria, can impede lincomycin entry. This limits the antibiotic’s access to its target, the ribosome.
Monitoring these resistance mechanisms through genomic sequencing and antimicrobial susceptibility testing helps guide treatment strategies and contributes to the development of new, more effective antibiotics.
